title: Antimetastatic activity of a preventive cancer vaccine.
abstract: The development of prophylactic cancer vaccines that protect healthy hosts from tumor development leaves open the question whether such vaccines are also effective against established tumors and metastases. We tested the therapeutic activity of a proven prophylactic anti-HER-2/neu vaccine against successive stages of mammary carcinoma progression in HER-2/neu transgenic mice. The vaccine consisted of transgenic mammary carcinoma cells expressing HER-2/neu and two adjuvants: allogeneic class I histocompatibility antigens and interleukin (IL)-12. Vaccination of mice bearing lung micrometastases resulted in a 90% inhibition of metastasis development, whereas vaccination of mice with incipient local tumors was ineffective. The antimetastatic response was hampered by immune tolerance, as the protection of transgenic mice was lower than that of wild-type congenics not tolerant to HER-2/neu. A significant gain in immunotherapeutic activity in transgenic mice was obtained through the coadministration of anti-CD25 monoclonal antibody targeting regulatory T cells, which resulted in a >99% inhibition of metastasis. The immune responses elicited in transgenic mice comprised the activation of lung granulocytes and macrophages and of systemic adaptive responses based on helper T cells and their cytokines (IFN-gamma and IL-4) and anti-HER-2/neu antibodies. Dissection of relevant antimetastatic mechanisms by means of knockout mice and of depleting antibodies revealed a major difference between tumor prevention, which was completely dependent on anti-HER-2/neu antibodies, and metastasis therapy, which was antibody independent. In conclusion, a vaccine successfully developed for cancer immunoprevention showed a strong therapeutic activity against lung metastases mediated by protective immune mechanisms distinct from those preventing the onset of primary mammary carcinoma.
authors.affiliation: Section of Cancer Research, University of Bologna, Bologna, Italy.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Nanni
authors.forename: Giordano
authors.initials: G
authors.lastname: Nicoletti
authors.forename: Arianna
authors.initials: A
authors.lastname: Palladini
authors.forename: Stefania
authors.initials: S
authors.lastname: Croci
authors.forename: Annalisa
authors.initials: A
authors.lastname: Murgo
authors.forename: Agnese
authors.initials: A
authors.lastname: Antognoli
authors.forename: Lorena
authors.initials: L
authors.lastname: Landuzzi
authors.forename: Marina
authors.initials: M
authors.lastname: Fabbi
authors.forename: Silvano
authors.initials: S
authors.lastname: Ferrini
authors.forename: Piero
authors.initials: P
authors.lastname: Musiani
authors.forename: Manuela
authors.initials: M
authors.lastname: Iezzi
authors.forename: Carla
authors.initials: C
authors.lastname: De Giovanni
authors.forename: Pier-Luigi
authors.initials: PL
authors.lastname: Lollini
mesh_terms: D000276:Adjuvants, Immunologic / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines; D045744:Cell Line, Tumor; D018450:Disease Progression; D007107:Immune System; D008175:Lung Neoplasms / Q000473:pathology; D015674:Mammary Neoplasms, Animal / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009362:Neoplasm Metastasis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D018719:Erb-b2 Receptor Tyrosine Kinases